Contributions
Abstract: P992
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Environmental risk factors
Introduction: vitamin D, a key environmental risk factor of MS, is predominantly influenced by ultraviolet B exposure from sunlight, but recent evidence suggests that also genetics and epigenetics are important determinants. The aim of the current study was to assess the presence of vitamin D pathway alterations related to MS risk.
Methods: patients admitted at our hospital between 2000 and 2013 for a clinically isolated syndrome (CIS) have been included. We evaluated baseline serum 25(OH)D and vitamin D metabolites levels as well as clinical, brain MRI and CSF data. Cox proportional models have been used to study the association between vitamin D metabolites and MS risk, and K-means clustering algorithms have been used to assess the presence of different vitamin D metabolism patterns.
Results: 120 CIS patients have been included in the study, and during follow-up (mean 7.71 years) 53.3 % of them developed the disease. Low levels of 25(OH)D or 1,25(OH)2D were significantly associated with a higher MS risk [HR 2.57 (CI, 1.19-5.56) and 2.56 (0.91-5.88)]. Among patients with medium or high levels of 25(OH)D two clusters have been identified, where the cluster with a significantly lower production of active and inactive metabolites (low CYP27 activity) had a significantly higher risk of MS (HR 3.85, CI 1.02-10).
Conclusions high 25(OH)D levels are associated with a lower MS risk, but 25(OH)D levels are not representative in the single patient of the final active form of vitamin D. In fact, 1,25(OH)2D is influenced by the activity of catabolic enzymes (CYP24) and activating enzymes (CYP271b), which could be altered in MS.
Disclosure: V.M. has received personal compensation for activities with Biogen, MerckSerono, Bayer Schering, TEVA and Sanofi as a speaker. G.C.has received compensation for consulting services and/or speaking activities from Bayer Schering, Serono, Merck Serono, Teva, Sanofi and Biogen. A.F., G.D.C, M.J.M., L.M., B.C., R.F, A.R., A.M.B. report no disclosures.
Abstract: P992
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Environmental risk factors
Introduction: vitamin D, a key environmental risk factor of MS, is predominantly influenced by ultraviolet B exposure from sunlight, but recent evidence suggests that also genetics and epigenetics are important determinants. The aim of the current study was to assess the presence of vitamin D pathway alterations related to MS risk.
Methods: patients admitted at our hospital between 2000 and 2013 for a clinically isolated syndrome (CIS) have been included. We evaluated baseline serum 25(OH)D and vitamin D metabolites levels as well as clinical, brain MRI and CSF data. Cox proportional models have been used to study the association between vitamin D metabolites and MS risk, and K-means clustering algorithms have been used to assess the presence of different vitamin D metabolism patterns.
Results: 120 CIS patients have been included in the study, and during follow-up (mean 7.71 years) 53.3 % of them developed the disease. Low levels of 25(OH)D or 1,25(OH)2D were significantly associated with a higher MS risk [HR 2.57 (CI, 1.19-5.56) and 2.56 (0.91-5.88)]. Among patients with medium or high levels of 25(OH)D two clusters have been identified, where the cluster with a significantly lower production of active and inactive metabolites (low CYP27 activity) had a significantly higher risk of MS (HR 3.85, CI 1.02-10).
Conclusions high 25(OH)D levels are associated with a lower MS risk, but 25(OH)D levels are not representative in the single patient of the final active form of vitamin D. In fact, 1,25(OH)2D is influenced by the activity of catabolic enzymes (CYP24) and activating enzymes (CYP271b), which could be altered in MS.
Disclosure: V.M. has received personal compensation for activities with Biogen, MerckSerono, Bayer Schering, TEVA and Sanofi as a speaker. G.C.has received compensation for consulting services and/or speaking activities from Bayer Schering, Serono, Merck Serono, Teva, Sanofi and Biogen. A.F., G.D.C, M.J.M., L.M., B.C., R.F, A.R., A.M.B. report no disclosures.